Homepage Top Section2

Under the terms of the worldwide exclusive licensing agreement, Pfizer will pay an upfront license fee of $250m to Akcea and Ionis. The fee will be split equally

Johnson & Johnson (J&J) will use the investment to advance research and development and delivery programmes to eliminate both diseases by 2030. The company will appoint a team

As per terms of the deal, Progenics shareholders will secure 0.2502 shares of Lantheus stock for each share of Progenics stock, representing around 35% aggregate ownership interest in

GPA and MPA are rare and potentially life-threatening diseases, which affect small and medium-sized blood vessels. The FDA approval was based on data from the PePRS phase IIa,

The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the treatment of cataplexy and excessive daytime sleepiness (EDS) in

Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is being developed

GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved therapies in the US. Earlier, the

The FDA has approved new drug applications (sNDAs) for Pifeltro in combination with other antiretroviral agents and Delstrigo as a complete regimen for adult patients with HIV-1 infection

The PREVENT trial is assessing the efficacy and safety of Cosentyx compared to placebo with the primary endpoint being ASAS40 at Week 16. All the secondary endpoints of